Chiyomi Egawa

Prognosis of Invasive Lobular Carcinoma and Effectiveness of Eribulin in Clinical Practice: A Post Hoc Analysis of a 2‐Year Post‐Marketing Surveillance

Yuko Tanabe, Kenichi Inoue, Masato Takahashi, Hirofumi Mukai et autres

AIM: Invasive lobular carcinoma (ILC) is the second most common breast cancer type after invasive ductal carcinoma (IDC). Eribulin mesylate (eribulin) is a non-taxane microtubule dynamics inhibitor approved for advanced or metastatic breast cancer, including ILC and IDC. However, real-world data from …

jp (code pays fourni par la source)

Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial

Takuji Iwase, Shigehira Saji, Kotaro Iijima, Kenji Higaki et autres

PURPOSE Treatment with an aromatase inhibitor for 5 years is the standard treatment for postmenopausal hormone receptor–positive breast cancer. We investigated the effects of extending this treatment to 10 years on disease-free survival (DFS). PATIENTS AND METHODS This prospective, randomized, multicenter open-label …

jp (code pays fourni par la source)

Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan

Masato Takahashi, Kenichi Inoue, Hirofumi Mukai, Takashi Yamanaka et autres

BACKGROUND: It was reported that eribulin regulates the tumor microenvironment, including the immune system, by inducing vascular remodeling. Lymphocyte counts are a critical index of immune response in patients. The non-Asian, global EMBRACE study has suggested that baseline absolute lymphocyte count (ALC) …

jp (code pays fourni par la source)

[Five Patients with Gastric Metastasis from Breast Cancer-A Case Report].

Masaki Otani, Takehiro Yanagawa, Kazuteru Oshima, Chiyomi Egawa et autres

Five patients with gastric metastasis from breast cancer were treated in our hospital. About the histopathological types of primary breast cancer, 4 patients were invasive ductal carcinomas and 1 was invasive lobular carcinoma. One patient was found by gastrointestinal fiberscopy for a …

jp (code pays fourni par la source)

[A Case of GIST That Recurred More Than 30 Years after Surgery and Could Be Resected].

Yoshiaki Ohmura, Yutaka Takeda, Yoshiteru Katsura, Go Shinke et autres

The patient was a 77-year-old woman. She underwent a partial gastrectomy at the age of 40, and a partial colectomy at the age of 75 following a diagnosis of a carcinoid. In November 2019, a 1.5 cm mass with a clear boundary …

jp (code pays fourni par la source)

Postoperative Adjuvant Anastrozole for 10 Rather than 5 Years in Patients with Oestrogen Receptor-Positive Breast Cancer: AERAS, a Randomised Multicentre Open-Label Phase III Trial

Takuji Iwase, Shigehira Saji, Kotaro Iijima, Kenji Higaki et autres

jp, ch (code pays fourni par la source)

[A Case of Stage Ⅳ Breast Cancer Treated with Mastectomy after Spontaneous Removal of a Cosmetic Breast Implant].

Ryota Mori, Ayako Yanai, Takehiro Yanagawa, Chiyomi Egawa et autres

A 51-year-oldwoman came to our hospital complaining of a skin ulcer in the left breast. She hadpreviously undergone cosmetic breast augmentation by placement of a bag prosthesis under each mammary gland. She was diagnosed with Stage Ⅳ(T4bN1M1)breast cancer with multiple bone metastases. …

jp (code pays fourni par la source)

[A Case of Solitary Fibrous Tumor of the Liver].

Yoshiaki Ohmura, Yutaka Takeda, Yoshiteru Katsura, Takuya Sakamoto et autres

Most solitary fibrous tumors(SFT)occur in the thoracic cavity and reports on liver SFT are very rare. We encountered a case of SFT of the liver, and thus, decided to report it with a review of literature. A 70-year-old man was informed of …

jp (code pays fourni par la source)

Abstract P5-12-07: Influence of aromatase inhibitor-related adverse events on the prognosis in postmenopausal Japanese patients with breast cancer: A prospective multicenter cohort study on patient-reported outcomes

Chiyomi Egawa, Shintaro Takao, K Yamagami, Masaru Miyashita et autres

Abstract Background Five-year adjuvant treatment with aromatase inhibitors is a standard treatment for postmenopausal women with estrogen receptor-positive breast cancer. However, aromatase inhibitor-related adverse events, including joint and vasomotor symptoms, have a strong impact on patient quality of life and sometimes cause …

jp (code pays fourni par la source)

Abstract P3-08-49: Baseline neutrophil-to-lymphocyte ratio and C-reactive protein predict efficacy of bevacizumab plus paclitaxel therapy for locally advanced or metastatic breast cancer

Hiromi Ozawa, Yoshimasa Miyagawa, Ayako Yanai, Takehiro Yanagawa et autres

Abstract Background Vascular endothelial growth factor (VEGF) is a key player in angiogenesis, and bevacizumab, a humanized monoclonal antibody against VEGF-A, is already utilized in daily clinical practice coupled with chemotherapy for locally advanced and metastatic breast cancers (ABC). Although the impact …

jp (code pays fourni par la source)

Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting

Kenichi Inoue, Masato Takahashi, Hirofumi Mukai, Takashi Yamanaka et autres

Background Data on eribulin as the first- or second-line treatment in a clinical setting, especially the overall survival (OS) of patients, are scarce. Therefore, we assessed the effectiveness and safety of eribulin as the first-, second-, and third- or later-line treatments in …

jp (code pays fourni par la source)

Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer

Yoshimasa Miyagawa, Ayako Yanai, Takehiro Yanagawa, Junichi Inatome et autres

// Yoshimasa Miyagawa 1 , Ayako Yanai 2 , Takehiro Yanagawa 2 , Junichi Inatome 2 , Chiyomi Egawa 2 , Arisa Nishimukai 3 , Kaori Takamoto 3 , Takashi Morimoto 3 , Yuichiro Kikawa 4 , Hirofumi Suwa 5 , Tomoe …

jp (code pays fourni par la source)